News and Trends 5 Jan 2017 Shire sells its RNA platform to a US-based Biotech Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […] January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 5 Jan 2017 What to Expect from European Biotech Finance in 2017 The new year comes with uncertainty over the future of the biotech industry, whose finance suffered during 2016. What are the expert predictions for 2017? Last year was the worst for biotech finance in a decade. Despite the struggle, some companies managed to make outstanding deals, fundraising and exits in 2016 and experts seem convinced that the […] January 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Jan 2017 Investors Jump on Hypersensitivity Peptides from GSK Spinout Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion, Fountain Healthcare Partners, Advent Life Sciences, Novo A/S, and Orbimed. NeRRe Therapeutics, a UK-based spinout of GSK, nailed down a €27M (£23M) Series B round. Helmed by […] January 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 Cold Sore Cure Company enters the Antibiotic Resistance fight AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 This British Biotech is buying its way into the Crowded NASH Space Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 Bacteria can Protect each other: a New Challenge in Antibiotic Resistance Researchers have discovered a new mechanism by which antibiotic-resistant bacteria can protect non-resistant pathogens. What are the implications? Scientists have described a new strategy that pathogens use to survive our efforts to eliminate them: resistant bacteria can inactivate antibiotics and allow their neighbor pathogens to grow once the active compound has reached low enough levels. The […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 New German Immuno-oncology Partnership takes on Solid Tumors TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jan 2017 An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […] January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jan 2017 Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV Intarcia will develop a drug delivery device for HIV prevention that can significantly reduce dosing frequency, backed by a €134M ($140M) deal with the Bill & Melinda Gates Foundation. Intarcia is a biotech unicorn from the US with an innovative drug delivery system that has managed to attract €197M ($206M) in Series EE, including €48M ($50M) from […] January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 2 Jan 2017 The Story behind one of the Most Successful Danish Biotech Entrepreneurs The series of profiles on impressive biotech leaders continues: John Haurum founded one of the most successful biotech companies in Denmark and is now leading one of the hottest European immuno-oncology companies. Here are some of his lessons and thoughts looking back at his rich career. John Haurum, born in Denmark, studied medicine at Aarhus University […] January 2, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 28 Dec 2016 Discussing the Future of Personalized Medicine with Biotech Experts Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […] December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email